Cue Biopharma (CUE) SEC Filings & 10K Form $0.75 +0.00 (+0.03%) As of 10:44 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share SEC Filings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Recent Cue Biopharma SEC Filings All Filing Types 1 10 10-D 10-K 10-M 10-Q 11-K 12b-25 13F 13H 144 15 15F 17-H 18 18-K 19b-4(e) 19b-4 19b-7 1-A 1-E 1-K 1-N 1-SA 1-U 1-Z 20-F 24F-2 25 2-E 3 4 40-F 5 6-K 7-M 8-A 8-K 8-M 9-M ABS DD-15E ABS-15G ABS-EE ADV ADV-E ADV-H ADV-NR ADV-W ATS ATS-R BD BD-N BDW C CA-1 CB CFPORTAL D F-1 F-10 F-3 F-4 F-6 F-7 F-8 F-80 F-N F-X ID MA MA-I MA-NR MA-W MSD MSDW n/a N-14 N-17D-1 N-17f-1 N-17f-2 N-18f-1 N-1A N-2 N-23c-3 N-27D-1 N-3 N-4 N-5 N-54A N-54C N-6 N-6EI-1 N-6F N-8A N-8B-2 N-8B-4 N-8F N-CR N-CSR N-MFP N-PX N-Q NRSRO N-SAR PF PILOT R31 S-1 S-11 S-20 S-3 S-4 S-6 S-8 SBSE SBSE-A SBSE-BD SBSE-C SBSE-W SCI SD SDR SE SF-1 SF-3 SIP T-1 T-2 T-3 T-4 T-6 TA-1 TA-2 TA-W TCR TH WB-APP X-17A-19 X-17A-5 Part I X-17A-5 Part II X-17A-5 Part IIA X-17A-5 Part IIB X-17A-5 Part III X-17A-5 Schedule I X-17F-1A Filing Types Include Ownership Filings Exclude Ownership Filings Only Show Ownership FIlings Ownership Filings Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel DateFilerForm TypeView04/25/20253:00 PMCue Biopharma (Filer)Form DEFA14A04/15/20253:44 PMCue Biopharma (Filer)Form 424B504/14/20254:17 PMCue Biopharma (Filer)Form 424B504/14/20253:00 PMCue Biopharma (Filer)Form PRE 14A03/31/20253:00 PMCue Biopharma (Filer)Form 10-KAnnual report pursuant to Section 13 or 15(d) 03/31/20253:00 PMCue Biopharma (Filer)Form 8-KCurrent report pursuant to Section 13 or 15(d) 03/21/20256:14 PMBleichroeder LP (Filed by)Cue Biopharma (Subject)Form SCHEDULE 13G/A12/18/20243:00 PMCue Biopharma (Issuer)PASSERI DANIEL R (Reporting)Form 4Statement of changes in beneficial ownership of securities 11/29/20243:00 PMBaker Daniel G. (Reporting)Cue Biopharma (Issuer)Form 3Initial statement of beneficial ownership of securities 11/29/20243:00 PMBaker Daniel G. (Reporting)Cue Biopharma (Issuer)Form 4Statement of changes in beneficial ownership of securities 10/07/20244:07 PMBleichroeder LP (Filed by)Cue Biopharma (Subject)Form SCHEDULE 13G/A10/04/20243:00 PMCue Biopharma (Filer)Form 8-KCurrent report pursuant to Section 13 or 15(d) 09/27/20243:17 PMCue Biopharma (Filer)Form 8-KCurrent report pursuant to Section 13 or 15(d) 09/27/20243:05 PMCue Biopharma (Filer)Form 424B509/26/20243:32 PMCue Biopharma (Filer)Form 424B509/10/20243:00 PMCue Biopharma (Filer)Form DEF 14A09/03/20243:30 PMCue Biopharma (Filer)Form 8-KCurrent report pursuant to Section 13 or 15(d) 08/28/20243:00 PMCue Biopharma (Filer)Form PRE 14A08/16/20243:00 PMCue Biopharma (Filer)Form 8-KCurrent report pursuant to Section 13 or 15(d) 07/25/20243:00 PMCue Biopharma (Filer)Form 8-KCurrent report pursuant to Section 13 or 15(d) (Data available from 1/1/2016 forward) Related Companies and Tools Related Companies MOLN SEC Filings KRRO SEC Filings IKT SEC Filings PRQR SEC Filings TNGX SEC Filings FDMT SEC Filings TLSA SEC Filings LFVN SEC Filings LRMR SEC Filings NBTX SEC Filings SEC Filings Tools Latest SEC FilingsInsider Trading Activity This page (NASDAQ:CUE) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cue Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cue Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CUE Stock Free CUE Stock Alerts